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1 | WHAT'S NEW IN SICK DAY
MANAGEMENT?
• The tried and true “Back to the Future” approach of frequent
monitoring of glucose and ketones, preferably of blood over urine
ketones, with timely administration of supplemental insulin along
with 24 hour, 7 day a week access to expert health care team advice
can successfully manage sick days and prevent progression to dia-
betic ketoacidosis (DKA) in young persons with insulin-treated
diabetes.
• Use of continuous glucose monitoring (CGM) devices may aid in
sick day management; greater penetration of CGMs with use of
CGM trend arrows for insulin dose adjustments can reduce glyce-
mic excursions and provide benefit.
• There are particular clinical situations when ketogenesis can be
common, such as in the setting of disordered eating behaviors,
use of SGLT1/2 inhibitors, and low carbohydrate diets, when fre-
quent glucose and ketone monitoring along with sick day manage-
ment are needed to prevent development of DKA.
2 | EXECUTIVE SUMMARY AND
RECOMMENDATIONS
The diabetes care team should provide clear guidance to patients and
families on how to manage diabetes during intercurrent illnesses, and
how to contact the diabetes team as well as emergency medical
personnel, if needed (24-hour diabetes team telephone contacts,
mobile telephones, emergency medical assistance procedures, etc.). In
addition to intercurrent illnesses, patients and families should feel
comfortable and be encouraged to call for help at times of misman-
agement, either accidental (missed insulin doses, incorrect timing of
doses [eg, AM given in PM], pump occlusion, etc.) or intentional (insu-
lin restriction, etc.) in order to avoid prolonged out-of-range glucose
levels and progression either to diabetic ketoacidosis (DKA) or severe
hypoglycemia. Reeducation should be repeated annually, for example,
at the time of annual flu shot administration, in order to avoid:




Patients and families/care providers should be reminded:
• Never to stop insulin completely [A]
• When vomiting occurs in a child or adolescent with diabetes, it
should always be considered a sign of insulin deficiency until
proven otherwise [E]
• The insulin dose usually needs to be increased (in addition to
usual dose) when there is fever, with many acute illnesses (except
for GI illnesses with emesis), during/following surgical procedures,
treatment with corticosteroids (eg, asthma flare, poison ivy,
nephrotic syndrome, etc.), and with any major stress based on
knowledge of clinical symptoms and signs and, especially, with
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awareness of monitored blood glucose and blood (or urine)
ketone levels checked frequently [E]:
1. Elevated blood glucose with absence or only small amount of
ketones:
• Give additional 5% to 10% of the total daily dose (TDD) of
insulin (~0.05-0.1 U/kg) as short or rapid-acting insulin sub-
cutaneously and repeat this same dose every 2 to 4 hours
according to blood glucose response and clinical condition.
Rarely, intramuscular insulin can be given although absorp-
tion may be no faster than with rapid acting analog. TDD of
insulin is the sum of all long, intermediate, and short/rapid-
acting insulins usually taken (for insulin pump users, TDD is
the sum of basal and bolus doses). One can also give 110%
of the calculated correction dose, repeated every 2 to
4 hours based on blood glucose response. For insulin pump
users, one can also increase the basal rate using a tempo-
rary basal rate with an increase of ~10% to 30% for 2 to
4 hours or longer as needed.
2. Elevated blood glucose with moderate or large amount of
ketones reflects actual or impending DKA with potential for
coma or death:
• Give additional 10% to 20% of the TDD of insulin
(~0.1-0.2 U/kg) as short or rapid-acting insulin subcutane-
ously and repeat this same dose every 2 to 4 hours accord-
ing to blood glucose response and clinical condition. Rarely,
intramuscular insulin can be given although absorption may
be no faster than with rapid acting analog. One can also
give 120% of the calculated correction dose, repeated every
2 to 4 hours based on blood glucose response. For insulin
pump users, one can also increase the basal rate using a
temporary basal rate with an increase of ~20% to 50% for
2 to 4 hours or longer as needed.
• Insulin doses may need to be increased considerably above the
10% to 20% increments in children who are in the partial remis-
sion or “honeymoon” phase when doses are relatively small; con-
sider providing supplemental doses per kg as noted above
(~0.05-0.1 U/kg or ~0.1-0.2 U/kg) [E].
• Monitoring blood ketones is preferred over urine ketones when
available (and affordable), and the use during illness can reduce
emergency room visits and hospitalizations [B]. Where blood
ketone testing is not possible, patients should be encouraged to
use urine ketone strips during illnesses and when blood glucose is
persistently elevated. During the recovery phase, urine ketones
(which measure acetoacetate) show improvement only after a cer-
tain lag period.
• Aim for a blood glucose between 4 and 10 mmol/L (70-180 mg/dL)
and blood ketones below 0.6 mmol/L when the child is ill [E].
• Use of continuous glucose monitoring (CGM) devices or intermit-
tently scanned glucose monitoring devices is helpful as a supple-
ment to blood glucose monitoring during illness and at times of
out-of-range glucose levels but one must ensure proper use of
such devices according to the manufacturer (and as emerging data
become available) due to need for calibrations (for certain devices)
and potential for inaccurate readings at extremes of glucose levels
with certain devices and from interfering substances like acet-
aminophen, aspirin, vitamin C, etc. [E].
• The insulin dose often needs to be decreased when there is gas-
troenteritis due to limited oral intake and/or malabsorption to
prevent hypoglycemia; however, one must ensure adequate basal
insulin delivery to prevent hyperglycemia and hyperketonemia
due to insulin deficiency [E].
• Hypoglycemia with hyperketonemia, which may occur in the set-
ting of GI illness or starvation, requires administration of insulin
along with carbohydrate intake [E].
• Maintaining hydration is essential in every child with diabetes
during an acute illness; oral fluids with or without sugar should be
consumed depending on the glucose level; consider timely initia-
tion of IV fluids if the child is unable to drink [E].
• In a child or adolescent with an intercurrent illness, URGENT spe-
cialist advice with possible referral to emergency care must be
obtained when [E for all below]:
• the underlying condition is unclear, fever persists, or family
members are uncomfortable providing home care for any
reason
• weight loss continues, suggesting worsening dehydration and
potential circulatory compromise
• vomiting persists beyond 2 hours (particularly in young
children)
• parents are unable to keep blood glucose above 3.9 mmol/L
(70 mg/dL)
• blood glucose level continues to rise despite extra insulin
doses
• fruity breath odor (acetone) persists or worsens
• blood ketones remain elevated >1.5 mmol/L or urine ketones
remain large despite extra insulin and hydration
• the child or adolescent is becoming exhausted, confused,
hyperventilating (Kussmaul breathing), or has severe abdominal
pain
• there is a change in neurologic status, mental confusion, loss of
consciousness, seizures, or progression of confusion to avoid
potential for cerebral edema; treatment of cerebral edema is a
medical emergency requiring immediate assistance with
advanced medical facilities to prevent morbidity and mortality
• the child is very young (<5 years old)
• there are comorbid conditions besides diabetes, making sick
day management more complex (eg, Down Syndrome, disor-
dered eating behaviors, mental illness, epilepsy, inflammatory
bowel disease, malaria, parasitic infections, etc.)
• patients/relatives are exhausted or do not have the facilities or
capability to provide needed care (eg, intellectual, emotional,
and/or financial constraints; unavailability of insulin or other
monitoring supplies, etc.)
• caretaker understanding/language problems make it difficult to
communicate with the family
• the patient and/or adult caretakers request advice and/or
emergency medical consultation; appropriate transport should
be facilitated as soon as possible according to local circum-
stances; the diabetes team should assist by contacting local
194 LAFFEL ET AL.
medical personnel, if possible, to ensure systems in place for
initial glucose and electrolyte monitoring along with IV fluids
and insulin, if needed, for emergency treatment while awaiting
evacuation to higher level facilities, as indicated.
An episode of DKA in a child with established diabetes could be a
signal that diabetes education along with assessment of family dynam-
ics needs thorough review, including home blood glucose and ketone
monitoring, insulin handling (injection, transport, storage, dosage, abil-
ity to adjust doses, etc.), potential for insulin manipulation, nonadher-
ence, family problems (or even abuse), as well as routine sick day
management. In addition, it may be useful to explain to family mem-
bers of low socioeconomic levels and those paying out of pocket for
insulin and supplies, who may restrict dosing as a means to save
resources, that even a single hospital admission is more expensive
than several weeks or months of home BG monitoring with insulin
administration, and, further that any episode of DKA could be life
threatening (see also Diabetic ketoacidosis and hyperglycemic hyper-
osmolar state: A consensus statement from the International Society
for Pediatric and Adolescent Diabetes).
3 | THE EFFECTS OF ILLNESS ON DIABETES
Children and teenagers whose diabetes is under good metabolic con-
trol should not experience more illness or infections than children
without diabetes. However, even routine childhood illnesses can make
diabetes management more challenging and increase the risk for DKA
or hypoglycemia (with gastroenteritis). While there are very few well
controlled, prospective studies about intercurrent illness in type 1 dia-
betes, one study of adult patients with type 1 diabetes reported a
higher risk of urinary tract, bacterial skin, or mucous-membrane infec-
tions although upper respiratory-tract infections were no more fre-
quent in patients with type 1 diabetes than in controls.1 There is some
evidence of impaired leukocyte function in poorly controlled diabetes
and children with poor metabolic control may have altered immune
function, increasing susceptibility to and delayed recovery from infec-
tion.2 One pediatric study found low IgG concentrations and reduc-
tion in complement protein 4, variant B (C4B) levels related to
impaired metabolic control.3 It is tempting to believe – but not scien-
tifically validated – that chronic hyperglycemia might be associated
with more problems.4 In many parts of the world, pediatric and ado-
lescent diabetes care is woefully inadequate because of a general lack
of resources, lack of health care systems, lack of expert diabetes care,
as well as enormous costs of diabetes care. These factors may contrib-
ute to chronic under-insulinization or marked glycemic variability in
youth, especially when insulin is too expensive, unavailable, or when
there is profound fear of hypoglycemia with inability to monitor glu-
cose levels adequately due to cost. In developing as well as developed
countries, occurrence of DKA remains a problem, therefore one must
have a high index of suspicion, especially among youth with poor met-
abolic control, that risk for DKA is high5 and prevention is key with
appropriate monitoring, insulin administration, and management of
intercurrent illnesses.4,6,7 In fact, a recent publication from national
surveillance DKA in the United States reported that hospitalization
rates for DKA have risen more than 50% from 2009 to 2014 for
persons <45 years of age.8 Infections and DKA continue to account
for significant mortality: a study from north India showed that infec-
tions and DKA were the commonest causes of death in type 1 diabe-
tes: 51.2% and 41.5%, respectively.9
Some illnesses, especially those associated with fever, raise blood
glucose levels because of higher levels of stress hormones promoting
glycogenolysis, gluconeogenesis, and insulin resistance.10 Illness often
increases ketone body production due to inadequate insulin levels
and the counter-regulatory hormone response. In contrast, illness
associated with vomiting and diarrhea (eg, viral gastroenteritis) may
lower glucose levels with the increased possibility of hypoglycemia
rather than hyperglycemia. Decreased food intake, poor absorption,
delayed gastric emptying, and/or overt diarrhea with more rapid tran-
sit time during gastroenteritis may contribute to hypoglycemia risk.
Sometimes, one may see increasing insulin requirements during the
incubation period of an infection for a few days before the onset of
the illness. The increased need for insulin may persist for a few days
after the illness has passed, presumably due to insulin resistance, but
insulin needs are highly variable from one person to another and from
one illness to the next. In the midst of a typical viral “epidemic,” how-
ever, patterns may occur that facilitate making some generalizations
to help advise subsequent patients/families.
Five general sick day diabetes management
principles:
1. Sick day guidelines, including insulin adjustments,
should be taught soon after diagnosis and reviewed at
least annually with patients and family members in order
to reduce risk for DKA and for severe hypoglycemia
(with GI illnesses).
2. More frequent blood glucose and ketone (blood or
urine) monitoring.
3. DO NOT STOP INSULIN.
4. Monitor and maintain hydration with adequate salt and
water balance.
5. Treat any underlying, precipitating illness.
3.1 | Sick day guidelines, including insulin
adjustments, should be taught soon after diagnosis
and reviewed at least annually with patients and
family members in order to reduce risk for DKA and
for severe hypoglycemia (with GI illnesses)
Sick day preparation
All families should receive education on sick day management. At
diagnosis, families can be overwhelmed with new information and it is
common for them to not retain information about sick day manage-
ment postdiagnosis.11 For this reason the information at diagnosis
should be simple, focusing on the importance of frequent monitoring
and not stopping insulin during an illness, and calling the health care
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team early for advice. As families become more competent with their
diabetes care, the sick day management education should be repeated
and extended to include specific education about the effects of inter-
current illness, hyperglycemia, ketosis, symptoms of DKA, DKA pre-
vention, sick day diet and fluids, and management of hypoglycemia
with mini-dose glucagon (if approach is available locally).12
Households should maintain readily available supplies and infor-
mation for sick day management including:
• Written information on management and important contact num-
bers/addresses of the health care team. Health care team avail-
ability by telephone has been shown in several clinical studies to
facilitate communication, allow for earlier advice and institution
of sick day guidelines, and decrease or minimize clinical decom-
pensation and even avoid emergency room use as well as
hospitalization.13–15
• Consider use of mobile apps for sick day management that are
available on smart phones and can be used by patients/families;
however, these apps should not replace communication with the
health care team.
• Sick day foods and hydration supplies such as chicken soup, elec-
trolyte drinks, etc.
• Sufficient glucose and ketone monitoring supplies, additional insu-
lin, and an emergency glucagon kit.
The health care team should tailor the education to suit the age
of the child/adolescent and development stage.16 For very young chil-
dren, families should receive appropriate advice on managing gastro-
enteritis and the need for early intervention and possible mini-dose
glucagon (see Table 2).12 Older teens should receive sick day manage-
ment education as they become more independent in their diabetes
self-management, although families should remain involved regardless
of age, as managing any intercurrent illness can be challenging without
support and guidance.
During the influenza season, health care professionals should
assess families' sick day management knowledge and review sick day
management plans.17 Families should be advised of the local recom-
mendations regarding influenza vaccination. Where influenza and
pneumococcal immunizations are available and recommended, for
example, in the United States by the American Diabetes Association
and the American Academy of Pediatrics, health care professionals
should encourage families to immunize their children and address any
expressed barriers to the uptake of immunizations, including concerns
they may have regarding managing minor side effects.
3.2 | More frequent monitoring
3.2.1 | Glucose
• Frequent blood glucose monitoring facilitates optimal manage-
ment during illness (with adult supervision, especially in adoles-
cents). This is not difficult for children routinely using CGM; the
parents and adolescent should keep a close eye on glucose
trends.
• Blood glucose should be monitored at least every 3 to 4 hours,
including through the night, and often every 1 to 2 hours.
• Urine glucose can be utilized if blood glucose monitoring
equipment is not available.4,6
• If routine blood glucose monitoring is not available, ideally
emergency glucose monitoring supplies should be “saved” for
episodes of illness (making sure the strips have been stored
properly and have not long expired), according to individual
local circumstances.18
• Distinguishing illnesses associated with hyperglycemia from those
associated with hypoglycemia is facilitated by BG
monitoring.4,6,19,20
• Insulin adjustments (sick day extra doses) and other insulin
changes take place in direct relationship to the ongoing blood glu-
cose monitoring results (see below).
3.2.2 | Ketones
Ketones are produced by the liver from free fatty acids that are mobi-
lized as an alternative energy source when there is lack of glucose for
intracellular metabolism, either from inadequate intake or inability to
utilize glucose in the setting of insulin deficiency. Starvation ketones
are produced when the blood glucose is low. Ketones are also pro-
duced when insulin is lacking to initiate the transport of glucose from
the blood stream into the cell. Ketones accumulate because of
increased lipolysis and increased ketogenesis, due to low insulin levels
and elevated counter-regulatory hormone levels. There are three
ketones: acetoacetate, acetone, and beta-hydroxybutyrate. Urine
ketone strips measure acetoacetate (AcAc) and acetone (if the strip
contains glycine), blood ketone strips measure beta-hydroxybutyrate
(BOHB), the predominant ketone in DKA, while most labs measure
serum acetoacetate. In acute ketoacidosis, the ketone body ratio
(BOHB:AcAc) rises from the usual level of 1:1 to 10:1 or more.21 In
response to insulin therapy, BOHB levels commonly decrease long
before AcAc levels do. The frequently employed nitroprusside test
only detects AcAc in blood and urine and so routine urine ketone
monitoring often shows prolonged ketonuria even when significant
ketoacidosis and hyperketonemia have already responded to treat-
ment.21 The prolonged ketonuria can result in confusion when there is
clinical improvement following successful sick day management. In
fact, if the persistent ketonuria leads to additional insulin administra-
tion when it is no longer needed, either at home or in emergency
rooms/hospital settings due to a desire to “clear” the urine ketones,
hypoglycemia can ensure. Monitoring blood ketones prevents this
problem as BOHB declines directly in response to insulin therapy. In
fact, declines in BOHB levels will be clinically evident even before
declines in blood glucose levels.4,6,14,22 Thus, blood ketone tests (for
BOHB), or urine ketone tests when blood ketone monitoring is una-
vailable, help to guide sick day management, with blood ketone testing
for BOHB providing additional information to urine ketone testing:
• Blood BOHB ≥0.6 mmol/L is abnormal in children with
diabetes.23,24
• Adult studies have shown that the time delay after a pump stop
to diagnose ketosis is significantly longer for ketonuria than for
plasma ketonemia25 and that urinary ketone tests can remain
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positive more than 24 hours after resolution of ketoacidosis in
the majority of patients.26
• There can be a dissociation between urine ketone (AcAc) and
blood BOHB concentrations such that urine ketone tests can still
be negative or show only trace or small ketone levels when blood
BOHB is already high, indicating need for treatment.4,27
• Following resolution of DKA, the dissociation between urine
ketones and blood ketones continues as urine ketone levels
remain elevated, and can lead to excess insulin administration and
risk for hypoglycemia if treatment is based on the urine ketone
result rather than the blood ketone result.
• Urine ketone supplies are inexpensive but may deteriorate within
a month or so after opening the bottle, so care may be needed to
ensure a fresh bottle is available if the previous bottle had been
opened more than a few months ago.
Home measurement of blood BOHB concentrations in children and
adolescents enables earlier identification and treatment of ketosis com-
pared to urine ketone testing, and decreases diabetes-related hospital
visits (both emergency department visits and hospitalizations).28–30
Patients should be encouraged to have home blood ketone test
strips. However, blood ketone strips can be unaffordable for many
households, may not be covered by insurance programs, or may not
be available. In these circumstances, urine ketone strips can be used
for sick day management. In countries where diabetes is uncommon,
or a low priority, patients/families should be encouraged to carry
the blood ketone strips with meter or urine ketone strips to the hos-
pital if the child needs admission, in case the hospital does not have
the facilities for ketone testing.
Blood BOHB measurements may be especially valuable to pre-
vent DKA in patients who use an insulin pump, as only rapid- or short-
acting insulin is used in this type of therapy. Elevations in blood BOHB
may precede elevations in urine ketones due to interrupted insulin
delivery22 (eg, catheter occlusion or dislodgement), which can rapidly
lead to ketogenesis and hyperketonemia, as well as increased insulin
needs. During resolution of ketosis, blood BOHB normalizes sooner
than urine ketones.4,6 Monitoring BOHB may also have the potential
to help prevent late hypoglycemia from overtreatment with insulin,
based upon the persistence of ketonuria while ketonemia is improv-
ing. Blood BOHB monitoring can be especially useful in very young
children, who cannot provide urine on demand, or in others who find
giving urine samples difficult.
3.3 | Never stop insulin
The insulin dose may need to be increased or decreased to maintain
glucose metabolism but it should never be stopped (see Table 1 for
insulin dosing recommendations).
• The most common mistake made by health care providers and
caregivers who are unfamiliar with diabetes is to recommend the
complete omission of insulin because “the child is ill and not
eating,” thus increasing the risk of frank DKA.4,6,10,18
• Even in the fasting state, some insulin is required for basal meta-
bolic needs, which may go up during an acute illness, when
counter-regulatory stress hormones are elevated, so that more
frequent monitoring of blood glucose and ketones is required to
direct insulin dosing.
• If episodes of hyperglycemia, ketosis, and vomiting recur, with or
without infection, it should be recognized that this may be due to
insulin restriction or omission.31 Insulin omission is particularly
problematic during adolescence32 and often represents a severe
psychosocial issue, for example, sexual or physical trauma, emo-
tional trauma or abuse, poorly treated or unrecognized anxiety or
depression, learning problems, executive dysfunction and/or atten-
tion deficit disorders, or some combination. Insulin restriction or
omission also may be used as a form of purging to lose weight,
representing a unique and dangerous form of disordered eating in
persons with type 1 diabetes.33 Family dysfunction or a psychiatric
illness in a caregiver is frequently seen in such circumstances, and
may contribute to the recurrence of DKA episodes either directly
or indirectly.34 Lack of appropriate adult supervision needs to be
considered, with appropriate therapeutic interventions put into
place, since recurrent DKA has a high association with DKA-related
complications, including coma and death.4,6,10,18–21
The insulin “cold chain” should also be reviewed. If the cold chain is
not maintained to the point of purchase (eg, the pharmacy may store in
a refrigerator, but it may have been exposed to high temperatures ear-
lier, at the warehouse level, for example), or if transport and storage are
not optimal (eg, carrying insulin home after purchase, or packing insulin
in baggage hold during a flight—insulin will freeze and then thaw), then
insulin potency may be affected, leading to impaired insulin action.35 It
may also be useful to inquire tactfully about number of insulin vials con-
sumed. If the insulin is purchased out of pocket, the parents may be
under-dosing due to financial constraints, but not documenting the
actual doses, out of embarrassment. Insulin injection technique should
be reviewed. Injecting persistently into hypertrophic areas, or not notic-
ing the presence of a large bubble in the insulin cartridge, can lead to
persistently high blood sugars, which may progress to DKA.
3.4 | Monitor and maintain hydration with salt and
water
• Hyperglycemia, fever, excessive glycosuria, and ketonuria all con-
tribute to increased fluid losses.
• Sick day cabinets should contain supplies as above to prevent
dehydration.
• Liquids for hydration should contain salt and water and not just
plain water, especially if there are ongoing losses associated with
vomiting or diarrhea. Chicken soup, consommé, home-made lem-
onade with both salt and sugar, or clear broths, are excellent
sources of water and electrolytes, which may be needed to main-
tain hydration and to avoid water and electrolyte imbalance in
conditions leading up to DKA.4,6,10,18–21 If appetite is decreased
or the glucose level is falling below 10 mmol/L (180 mg/dL),
sugar-containing fluids should be considered to decrease risk of
starvation ketosis, along with insulin at an adjusted dose. It may
be helpful to remove excessive carbonation (bubbles) in some soft
drinks to minimize potential for indigestion. This can be achieved
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<0.6 mmol/L Negative/trace • Give ordinary bolus • Add +5% TDD or 0.05 U/kg to
ordinary bolus
• Add +10% TDD or 0.1 U/kg to
ordinary bolus
• Oral sugar-free fluids
0.6-0.9 mmol/L Trace/small • Add +5% TDD or + 0.05 U/kg
to ordinary bolus or give 105%
of calculated correction bolus
• Oral sugar fluids
• Add +5%-10% TDD
or 0.05-0.1 U/kg to ordinary
bolus or give 105%-110% of
calculated correction bolus
• Oral sugar-free fluids
• Add +10% TDD or 0.1 U/kg to
ordinary bolus
• Oral sugar-free fluids
1-1.4 mmol/L Small/moderate • Add +5%-10% TDD or 0.05-0.1
U/kg to ordinary bolus or give
105%-110% of calculated
correction bolus
• Oral sugar fluids
• Extra CHOa
• Add +10% TDD or 0.1 U/kg to
ordinary bolus or give 110% of
calculated correction bolus
• Oral sugar-free fluids
• Add +10% TDD or 0.1 U/kg to
ordinary bolus
• Oral sugar-free fluids
1.5-2.9 mmol/L Moderate/large • Add +5%-10% TDD or 0.05-0.1
U/kg to ordinary bolus or give
105%-110% of calculated
correction bolus
• Oral sugar fluids
• Extra CHOa
• Add +20% TDD or 0.1-0.2 U/kg
to ordinary bolus or give 120%
of calculated correction bolus
• Oral sugar-free fluids
• Add +20% TDD or 0.1 U/kg
to ordinary bolus
• Oral sugar-free fluids
• If vomiting, consider IV saline
+5% glucose solution
≥3 mmol/L Large • Add +10% TDD or 0.1 U/kg to
ordinary bolus or give 110% of
calculated correction bolus
• Oral sugar fluids
• Extra CHOa
• Add +20% TDD or 0.1-0.2 U/kg
to ordinary bolus or give 120%
of calculated correction bolus
• Oral sugar-free fluids
• Add +20% TDD or 0.1 U/kg
to ordinary bolus
• Oral sugar-free fluids
• If vomiting, consider IV saline
+5% glucose solution
Risk of ketoacidosis! Consider DKA protocol and transfer to emergency department
Check BG and ketones every 2 hours, repeat additional insulin if needed every 2-4 hours
B. Insulin reduction
Normoglycemia/hypoglycemia
Ketones (starvation) Blood glucose




<0.6 mmol/L Negative/trace • No extra insulin
• Reduce TDD insulin 20%
• Oral sugar fluids and extra CHOa
• If BG < 70 mg/dL à hypo correction
(consider mini-dose of glucagon)
• No extra insulin
0.6-0.9 mmol/L Trace/small • Reduce TDD insulin 15%
• Give ordinary bolus
• Oral sugar fluids
• Extra CHOa
• Oral sugar fluids
• Extra CHOa
1-1.4 mmol/L Small/moderate • Reduce TDD insulin 10%
• Give ordinary bolus
• Oral sugar fluids
• Extra CHOa
• Give ordinary bolus
• Oral sugar fluids
• Extra CHOa
1.5-2.9 mmol/L Moderate/large • Do not reduce TDD insulin
• Give ordinary bolus
• Oral sugar fluids
• Extra CHOa
• If vomiting, cannot eat or drink, consider
IV saline +5% glucose solution
• Add +5% TDD or 0.05 U/kg to ordinary bolus
• Oral sugar fluids
• Extra CHOa
≥3 mmol/L Large • Do not reduce TDD insulin
• Give ordinary bolus
• Oral sugar fluids
• Extra CHOa
• If vomiting, cannot eat or drink, consider
IV saline +5% glucose solution
• Add +5% TDD or 0.05 U/kg to ordinary bolus
Risk of ketoacidosis
Check BG and ketones every 2 hours
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by opening the containers and allowing time for bubbles to
escape along with a little shaking or stirring. Carbonated fluids
may alter the distribution of food within the stomach and may
contribute to bloating in some patients.36
• Elevated levels of ketones, whether associated with hypoglycemia
(starvation ketosis) or hyperglycemia and insulin deficiency, can
contribute to nausea and may lead to decreased food and fluid
intake, exacerbating dehydration and ketosis, increasing the risk
for DKA. 4,6,10,18–21
• Intravenous fluids may be required if nausea, vomiting, or diarrhea are
persistent with ongoing weight loss, especially in young children who
are at great risk for dehydration without adequate enteral intake.
Loss of appetite
Replacing meals with easily digestible food (eg, rice-lentil broths and
sugar-containing fluids) that provide energy (carbohydrates) can help
prevent starvation ketosis as long as insulin is given. Necessary sick
day management supplies at home include the following:
• glucose tablets, sweets, or candies such as jelly beans or sucking
candies as well as dried fruits to prevent hypoglycemia
• clean (boiled/purified as necessary) water to provide hydration
• sugar and electrolyte containing fluids such as sports drinks,
home-made lemonade with sugar and salt, electrolyte mixtures, or
sugar-containing soft drinks or sodas to provide hydration, glu-
cose, and salts
• easy to digest carbohydrates such as crackers, noodles, rice, or yogurt.
3.5 | Treat any underlying precipitating illness
Specific medical advice: Treat any underlying precipitating
illness
The underlying illness should be treated as recommended for any child
or adolescent without diabetes (ie, antibiotics for bacterial infections,
etc.). In some parts of the world, specific endemic or epidemic ill-
nesses have to be considered (eg, dengue hemorrhagic fever [DHF],
malaria, gastrointestinal parasitic infections, etc.). Monitoring for clini-
cal manifestations of some diseases may be complicated in patients
with diabetes in whom insulin deficiency alone can present like a gas-
trointestinal illness with nausea and vomiting, although one would not
expect any diarrhea from insulin deficiency. Treating fever, malaise,
and headache with antipyretics or pain medications such as paraceta-
mol (ie, acetaminophen) or ibuprofen is reasonable, as long as no aller-
gies to these medications exist. Consider instructing patients and
families to include acetaminophen suppositories with their sick day
supplies for times when enteral intake may be difficult, such as with
gastroenteritis. Additionally, one must exercise caution when taking
acetaminophen or acetaminophen-containing cold medications in per-
sons using certain CGM devices that exhibit interference from these
medications.37,38 Notably, some newer generations of CGM no longer
experience acetaminophen interference.39,40
Nausea and vomiting warrant careful scrutiny as vomiting can be
caused by either:
i. an illness itself (ie, gastroenteritis, unclean food or food poisoning,
surgical condition, other illness, etc.)
ii. severe hypoglycemia
iii. insulin deficiency resulting in hyperglycemia and ketosis, and risk
for DKA.
For vomiting in association with gastroenteritis, one can consider
treatment with anti-nausea medications, if available and if there is no
known allergy or other medical contraindication to such treatment.
Anti-nausea medications can include injectables or rectal suppositories
of antiemetics (eg, ondansetron, promethazine, etc.), as oral intake of
such medications may be difficult with ongoing emesis. Some patients/
families have had success with oral antiemetics like ondansetron if
given in a timely manner early in the course of the illness, or just after a
bout of vomiting. Such medications would be contraindicated with any
mental status changes. These medications also should be used cau-
tiously with food poisoning, when they may be contraindicated. Addi-
tionally, one must be especially cautious if the nausea and vomiting are
due to DKA, when DKA management is the treatment, and not
antiemetics.
Until the vomiting settles, it may be best to take small sips of cool
liquids, which are better tolerated than warm liquids. Hydration can
be aided by sucking on frozen pops or frozen juice bars (either sugar-
free in the setting of hyperglycemia, or sugar-containing when glucose
Abbreviations: BG, blood glucose; CHO, carbohydrate; TDD, total daily dose.
Ordinary bolus = insulin dose for usual correction and/or carb intake. To calculate the TDD, add up all the insulin given on a usual day (ie, short/rapid and
long/intermediate acting) or sum daily basal rates and boluses in a pump. Do not include additional boluses given for correction of hyperglycemia. In chil-
dren and adolescents with usual low (<0.7 U/kg/d) or usual high (>1 U/kg/d) insulin requirements, consider using the percentage (%) calculation rather
than empirical 0.05 to 0.1 to 0.2 U/kg supplemental dose. High BG and elevated ketones indicate a lack of insulin. “Starvation” blood ketone levels are usu-
ally <3.0 mmol/L. When the child is feeling sick or vomiting and ketone levels are negative or low (trace or small) with BG <10-14 mmol/L (<180-250 mg/
dL), he/she must try to drink sugar-containing fluids in small amounts (at least 100 mL/h) to keep BG up. When ketone levels are elevated, priority is to
give extra insulin. If BG is simultaneously low, IV saline 5% dextrose solution may be required. Additional doses of insulin are always short or rapid-acting.
Short-acting insulin can be given intramuscularly to speed up absorption. The ketone level may increase slightly (10%-20%) within the first hour after giving
extra insulin, but afterwards it should decrease. Blood ketones (BHOB) normalize sooner than urine ketones. If the child's glucose levels are persistently
elevated or the illness is expected to last ≥3 days, consider increasing long/ intermediate acting insulin or the basal rates delivered by pump by 10%-20%
(even higher, up to 50% by pump at times, if needed) during the expected sick days and reduce gradually as the illness subsides [E].
a Extra carbohydrates if tolerated.
TABLE 2 Recommended dose for mini-dose glucagon
Quantity
Age (y) Micrograms mg cc's (1 mg/cc)
Units on insulin
syringe
<2 20 0.02 0.02 2






1 per year of
age
>15 150 0.15 0.15 15
Note that the doses recommended above are quite different (lower) from
emergency doses given in case of severe hypoglycemia.
TABLE 1 (continued)
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is low or falling). When the blood glucose is elevated and ketosis is
present, extra insulin must be administered even when there is ongo-
ing nausea and vomiting. In fact, the vomiting may stop once extra
insulin has been given, due to management of the ketosis.
Oral medicines for symptomatic relief of gastroenteritis have no
proven efficacy and are therefore not usually recommended. Infectious
diarrheal illnesses are best managed in their locales when the local
health care teams should be aware of the proper medications, and if
any are indicated. Unknown or uncertain alternative medicines should
be avoided; sick day education efforts should include discussion of safe
and unsafe management efforts with a review of all medications.
4 | INSULIN DOSING RECOMMENDATIONS
FOR SICK DAY MANAGEMENT:
4.1 | Additional insulin:
• Additional doses of rapid-acting or short-acting insulin are
required to reduce blood glucose, turn off ketogenesis,
and prevent progression to ketoacidosis and hospital
admission.4,6,7,21
• The additional doses are always rapid-acting insulin analogs or
short acting insulin (synthetic or animal-origin), if only the latter is
available due to cost.
• The dose and frequency of injecting or bolusing will depend on
the level and duration of hyperglycemia and on the severity of
ketosis. Such supplemental doses are usually given subcutane-
ously but may also be given intramuscularly with health care pro-
fessional advice.
• The additional dose of insulin is calculated as a percentage of the
total of rapid/short acting and long/intermediate acting insulins
for the day (or the total of bolus and basal insulin given by a
pump), defined as the TDD. Supplemental doses of insulin are
always given in addition to the usual insulin dose.
• If there is hyperglycemia without hyperketonemia or no more
than small ketonuria, usual recommendations are to give an addi-
tional, supplemental injection or bolus of rapid-acting or short-
acting insulin calculated as 5% to 10% of the TDD, or approxi-
mately 0.05 to 0.1 U/kg, if the TDD is unknown. This supplemen-
tal dose, given in addition to the usual dose for carbohydrate
coverage and correction, should be repeated every 2 to 4 hours,
based upon blood glucose and ketone monitoring results. One
can also give 110% of the calculated correction dose, repeated
every 2 to 4 hours, based on response (see Table 1A).
• If there is hyperglycemia with hyperketonemia, or moderate to
large ketonuria, usual recommendations are to give an addi-
tional, supplemental injection or bolus of rapid-acting or short-
acting insulin calculated as 10% to 20% of the TDD, or approxi-
mately 0.1 to 0.2 U/kg, if the TDD is unknown. This supple-
mental dose, given in addition to the usual dose for
carbohydrate coverage and correction, should be repeated
every 2 to 4 hours, based upon frequent blood glucose and
ketone monitoring results. One can also give 120% of the cal-
culated correction dose, repeated every 2 to 4 hours, based on
response (see Table 1A). The additional dose recommendation
of 0.05 to 0.2 U/kg is a general recommendation for children
and adolescents with standard insulin requirements of approxi-
mately 0.7 to 1.0 U/kg/d. However, for children or adolescents
who have low usual daily insulin requirements, or those with
insulin resistance and high daily insulin requirements, the per-
centage calculations may work more readily rather than the
empiric U/kg additional dose.
• When children or adolescents are in the “honeymoon” remission
phase and insulin doses are relatively small, there may be a need
to increase supplemental insulin doses; consider providing supple-
mental doses per kg as noted above (~0.05-0.1 U/kg or
~0.1-0.2 U/kg) and assess response, as the standard supplemental
dose of 10% to 20% of the TDD may be insufficient to lower the
glucose levels in a timely manner.
• During illness it may also be necessary to increase basal insulin
doses, whether given as a long-acting insulin analog or intermedi-
ate insulin in injection-based therapy, or as a basal rate when
using an insulin pump. With a pump, temporary basal rate
increases of 20% to 50%, or higher at times, may be needed until
the blood glucose level improves and ketone levels return to nor-
mal (BOHB <0.6 mmol/L or negative to small urine ketones).
Note, it may be necessary to increase the maximum hourly basal
rate that the pump can deliver when using temporary basal rate
increases for sick day management.
Example: A sick child has a blood glucose level of 14 to
20 mmol/L (ie, 250-360 mg/dL) with blood ketones of
1.5 mmol/L (or moderate urine ketones). The family is
advised to give a supplemental insulin dose of 10% to
20% of the TDD (or 0.1-0.2 U/kg) as rapid-acting
(or short-acting) insulin every 2 to 4 hours until the
blood glucose falls to <14 mmol/L (<250 mg/dL) and
the blood ketones are <0.6 mmol/L (or urine ketones
are negative to small). Thereafter, any additional doses
might be 5% to 10% of the TDD (or about half of the
previous supplemental dose). Blood glucose should be
checked every 2 to 3 hours, and blood ketones should
be checked every 1 to 2 hours, as the blood ketones
will fall faster than the blood glucose. Urine ketones
should be checked at each void, if blood ketone moni-
toring is unavailable.
• After extra insulin has been given, the blood ketone level may
temporarily increase by 10% to 20% for the first hour or two but
should be expected to decrease thereafter.
• Urine ketones often stay elevated for many hours because of the
body's conversion of blood BOHB into AcAc, which is measured
with urine testing.4,6,21
• If blood ketone level is ≥3 mmol/L (or the urine ketones remain
large) despite extra insulin and hydration, consider referral to the
emergency room for assessment and IV fluids, as the risk for DKA
is high (see Table 1).
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4.2 | Infections associated with hypoglycemia
• Infections associated with hypoglycemia usually involve the GI
tract, with viral gastroenteritis as the most common. Such ill-
nesses are often associated with nausea and vomiting, and can
occur with or without diarrhea. Hypoglycemia occurs due to
reduced enteral intake with nausea and vomiting, altered gastric
emptying, malabsorption, and more rapid GI transit time associ-
ated with diarrhea. Occasionally, patients and families may report
unexplained hypoglycemia as a prelude to viral gastroenteritis,
even prior to the first bout of emesis. Additionally, hypoglycemia
may continue beyond the symptomatic stage of nausea and
vomiting as malabsorption may persist a few days longer as the
gut heals. During such illnesses, it is reasonable to advise repla-
cing meals with small volumes of sugar-containing drinks for calo-
ries, provided with appropriate insulin coverage, along with fluids
that contain electrolytes, as noted above. A simple diet can be
reintroduced that may include rice, crackers, applesauce, bananas,
tea, bread, yogurt, and potatoes, for example, depending on avail-
ability and local custom. Frequent blood glucose monitoring can
guide temporary insulin dose reductions, recalling that insulin
should never be totally stopped.4,6,18–20
• Include sugar-containing drinks with insulin coverage.
• Give sufficient fluids to maintain hydration, keeping records of
how much the child has had to drink.
• Attend to urine output and follow body weight, if available at
home, every 4 to 6 hours. Steady weight suggests adequate
hydration and fluid replacement, whereas ongoing weight loss
usually requires contact with the health care team to assess need
for emergency room assessment or hospitalization for intravenous
fluid treatment.
• Reduce total daily insulin dose by 20% to 50% during GI illnesses
associated with hypoglycemia, generally beginning with a 20%
reduction of the basal or intermediate acting insulins and a 50%
reduction of the bolus dose, which may be given after eating to
ensure intake of the prepared drink and/or food. Ongoing fre-
quent monitoring is needed because an excessive dose reduction
may lead to insulin deficiency and risk for ketosis and
ketoacidosis.
• Check ketones along with blood glucose as a guide to determine
if starvation ketosis is occurring. Such ketones in association with
hypoglycemia reflect inadequate energy supply and indicate a
need for carbohydrate intake with insulin.
• If hypoglycemia persists with blood glucose levels <3.9 mmol/L or
(<70 mg/dL) along with nausea, vomiting, anorexia, or food
refusal, a modified, smaller-than-usual dose of glucagon, if avail-
able, can be given, termed “mini-dose glucagon.” Mini-dose gluca-
gon can increase the glucose level back into a safe range as long
as there are adequate glycogen stores in the liver, which can be
deficient following prolonged vomiting or fasting. Nonetheless, it
is safe to try mini-dose glucagon in such circumstances12,41 (see
Table 2). The mini-dose is most easily administered using an insu-
lin syringe after reconstituting the glucagon with the diluent pro-
vided in the glucagon kit. The dose begins with 0.02 mg (equal to
2 U on an insulin syringe) for children up to age 2 years and then
increases by 0.01 mg (1 U on an insulin syringe) per year of life up
to a max dose of 0.15 mg (15 U on an insulin syringe). The
mini-dose can be repeated after 30 to 60 minutes, if needed. If
hypoglycemia persists and/or glucagon is not available, emer-
gency services will be required for IV fluids containing dextrose.
In the interim, simple sugar, like honey, molasses or cake frosting,
can be given in the buccal cavity for rapid absorption by the oral
mucosa, as long as there is no risk of aspiration. Of note, intrana-
sal preparations of glucagon for easier administration have been
studied and may become available soon.42
5 | SPECIAL CONSIDERATIONS
5.1 | Insulin dose reductions for GI illnesses
• If there is normoglycemia (5-10 mmol/L or 90-180 mg/dL) with-
out ketone elevations, oral fluids with sugar should be offered
along with appropriate insulin coverage, with ongoing monitoring
of blood glucose and ketone levels every 2 hours. Frequent moni-
toring will guide insulin dosing reductions (see Table 1B).
• If there is normoglycemia (5-10 mmol/L or 90-180 mg/dL) with
elevated blood or urine ketone levels, continue to give usual insu-
lin doses with ongoing monitoring.
• If blood glucose is low (<3.9 mmol/L or <70 mg/dL), consider
mini-dose glucagon.
• If vomiting persists beyond 2 hours, especially in children under
5 years old, or if hypoglycemia cannot be corrected, refer for IV
fluids with dextrose along with continued monitoring.
5.2 | Specific advice regarding sick day management
for children and adolescents receiving insulin pump
therapy
The key points of sick day management, mentioned previously, are
the same for pump users as for those receiving insulin injec-
tions.20,43,44 Patients on pumps use only rapid- or short-acting insulin
and do not have any injected depot of long-acting insulin so DKA can
develop rapidly, with either interruption of insulin delivery, or during
an intercurrent illness when no increased insulin is given. Episodes of
hyperglycemia must be taken very seriously, especially if associated
with elevated blood or urine ketones. If the blood glucose level is
14 mmol/L (~250 mg/dL) or above in a child or adolescent using an
insulin pump, the following steps should be taken:
• Check for ketones in the blood or urine.
• Immediately check for problems with the pump or delivery sys-
tem. Common problems include kinks in the catheter, air in the
infusion line, disconnected catheters especially at the insertion
site, and insertion site irritation. These can be identified when the
patient and family change the infusion set immediately upon rec-
ognition of hyperglycemia that cannot otherwise be explained.
• Give a correction dose of insulin by syringe, based upon the blood
glucose and ketone levels and not by the insulin pump, even after
LAFFEL ET AL. 201
the infusion set has been changed, in order to be certain that
insulin is being delivered.
• Proceed with dosing and monitoring as directed in Table 3,
depending on the glucose and ketone results. In cases of ketosis,
always be sure to give the extra insulin with a pen or syringe to
ensure delivery, and not with the pump, as malfunction may be
the cause of ketosis.
• Subsequent correction boluses are increased by 10% to 20% dur-
ing the period of illness, according to the glucose and ketone
results, and can be given by pump once the infusion has been
changed.
• To provide for extra basal insulin during sick days, the basal rate
can be increased by 20% to 50%, according to glucose and ketone
results.
• Meal insulin boluses may need to be decreased during GI illnesses,
as noted above, when hypoglycemia is a concern.
• Basal insulin rates can also be decreased by 20% to 50% when
hypoglycemia is a concern, as a temporary basal rate reduction
for 2 to 4 hours or longer, as needed based on ongoing glucose
and ketone monitoring.
5.3 | Final considerations for sick day management
in the current era of emerging technologies and
adjunctive therapies
There are many new advances for the care of young persons with dia-
betes, although regulatory approvals for the pediatric population often
lag behind approvals for adults with diabetes. Nonetheless, the cur-
rent era of diabetes management tools includes increasing use of
CGM devices and emerging use of automated insulin delivery systems.
Sick day management guidance should likely rely mainly on blood
glucose results obtained by fingerstick along with blood ketone moni-
toring, preferably over urine ketone monitoring. However, certain
CGM devices have received regulatory approval for nonadjunctive
use; in other words, the CGM results can be used for management of
low and high glucose levels. Due to the risk of DKA during sick days, it is
wise to confirm CGM results with blood glucose monitoring to ensure
timely delivery of extra insulin to avoid progression to DKA. However,
CGM trend arrows may be helpful in managing sick days as the CGM
device can signal whether the glucose is continuing to rise, fall, or is
remaining stable. Recent guidelines have been published that recom-
mend insulin dose adjustments according to the trend arrows on cer-
tain CGM devices.45 Children and adolescents using automated
insulin delivery devices should likely change to manual mode during
sick days in order to ensure adequate supplemental insulin delivery.
Finally, adjunctive use of the new class of oral agents called
SGLT2 (or SGLT1/2) inhibitors have been reported to increase risk for
DKA in patients with type 1 and type 2 diabetes. The greatest concern
stems from the DKA risk, which can occur at times in the absence of
extreme hyperglycemia, especially in the setting of “low carb” diets or
low carbohydrate intake.46,47 Any patient receiving SGLT1/2 inhibi-
tors must receive rigorous sick day management education to avoid
progression to DKA. This includes training on the use of blood ketone
monitoring of BOHB as atypical or euglycemic DKA has been reported
and therefore typical blood glucose warning levels for DKA may be
inadequate if SGLT1/2 inhibitors are being taken.
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TABLE 3 Management of sick days and hyperglycemia with insulin pump 8 [E]
Ketones negative:
Blood ketones >0.6 mmol/L or positive urine ketones or apparent that pump is not
working or catheter blocked, dislodged etc:
Give correction bolus with pump May be a pump delivery or site problem or an illness.
Test BG hourly to confirm that BGs move downward Give sick day bolus by injection with pen or syringe using Table 1 guidelines for sick day
booster 5-10-20% rule
Drink low-carbohydrate fluids or salty liquids (ie, soup) Change the catheter, tubing, and insulin reservoir and check to be sure pump is working
If BG lower after 1 hour, recheck again in 1-2 more hours
to decide if another bolus is needed
Continue to follow sick day booster guidelines using pen or syringe until BGs respond
If BG not lower on recheck, then give bolus by syringe or
pen and follow instructions in second column
Re-establish insulin pump infusion with new set and cannula with temporary basal rate
increase of approximately 120%-150% depending upon BG and ketone results
Monitor BG hourly and recheck ketones and weight at least every 4 h
Drink extra high-carbohydrate fluids if the ketones are elevated and BG is low and extra
low-carbohydrate “diet” fluids if BG is elevated with or without elevated ketones
If after 2 h there is no improvement, liaise with diabetes pump team. If after 2 h the BG
is improved, use the unused bolus rule to decide if an additional bolus is neededa.
Pump use can be resumed.
BG remains high, ketones persist, or nausea, vomiting, or abdominal pain develop,
confusion or problems staying awake and alert, contact the diabetes pump team or
proceed to immediate hospital assessment.
a Correction doses given for hyperglycemia should take into consideration the residual effect of any previous meal or correction bolus dose. A useful guide
is to use the “unused bolus rule” (approximately 30% of a rapid-acting insulin bolus is absorbed each hour). The correction dose should be reduced
accordingly. For example, if 5 units had been given as a meal bolus 2 h previously, 60% would have been absorbed and the remaining 40% or 2 units
would still be exerting an effect. This should be subtracted from any correction dose. However, most pumps have this “insulin on board” included in the
“bolus guide,” and you need then not subtract it manually if this function is activated.
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